Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities

Accrued Liabilities and other Long-Term Liabilities

3 Months Ended

Mar. 31, 2019

Payables and Accruals [Abstract]

Accrued Liabilities and other Long-Term Liabilities

12. Accrued Liabilities and other Long-Term Liabilities

Accrued expenses and other long-term liabilities consisted of the following:

($ in thousands)	March 31, 2019		December 31, 2018
Accrued expenses:
Professional fees	$	1,262	$	1,434
Salaries, bonuses and related benefits		5,592		5,843
Accrued expenses - related party		16		–
Research and development		4,855		3,805
Research and development - milestones		–		200
Research and development - manufacturing		826		826
Research and development - clinical supplies		215		160
Research and development - license maintenance fees		489		519
Dr. Falk Pharma settlement		300		300
Accrued royalties payable		1,233		1,108
Accrued coupon expense		993		838
Other		4,546		1,327
Total accrued expenses	$	20,327	$	16,360

Other long-term liabilities:
Deferred expenses related to build-out 1		2,276		5,211
Total other long-term liabilities	$	2,276	$	5,211

Note 1: As of March 31, 2019, balance consists of deferred charges related to build-out of the New York facility, and as of December 31, 2018, balance consists of deferred rent and deferred build out charges.